Journals
2026 EN
Ritch Elaine L. · Siddiqui Noreen Q. · Canning Catherine
ABSTRACT The financially lucrative fast‐fashion business strategy is criticised for impacting detrimentally on the environment, with marketing tactics encouraging frequent‐impulsive fashion consumption. This research presents a novel conceptual framework merging fashion involvement values within prospect theory, creating a fashion‐identity‐time‐horizon lexicon which is examined within three generational cohorts (Z, Y and X). Dyadic interviews with 12 participants provided rich and insightful data, with analysis revealing four theoretical contributions to knowledge: (1) fast‐fashion marketing encourages passive consumption, (2) fashion fads differ from fashion style, (3) the same medium that stimulates fast fashion can be used to promote the circular economy and (4) confidence in fashion evolves with maturity. Managerial contributions include practical ways in which fast‐fashion retailers can shift towards a more environmentally focused business strategy that would appeal to consumers' fashion identities and time horizons, as well as sustainability values. Recommendations are made to align with regulations emerging from France to curb fast‐fashion sales.
Journals
2026 EN
Chi Ellenor · Chang Derek K. · Chang ChunPin Esther
+7 more
ABSTRACT Purpose Advancing therapies have increased B‐cell Non‐Hodgkin's Lymphoma (B‐NHL) patient survival. However, data are limited on the risk of type II diabetes mellitus (type II DM) in adult survivors following treatment. This study examines the risk of type II DM among a Utah population of B‐NHL survivors, compared to the general population. Methods A cohort of 3529 adult survivors diagnosed with B‐NHL in Utah between 1997 and 2013 in the Utah Cancer Registry and 13,339 individuals from the general population were identified using the Utah Population Database (UPDB). Multivariate Cox Proportional Hazard models were used to estimate adjusted hazard ratios (aHR) for developing type II DM, stratified for time post‐diagnosis. Results Compared to the cancer‐free population, B‐NHL survivors had an overall increased risk of developing type II DM (HR: 1.49; 95% CI: 1.32, 1.69), largely within the first year (HR: 4.41; 95% CI: 3.52, 5.52) following diagnosis. Older B‐NHL survivors were more likely to develop type II DM at any time compared to survivors < 40 years [40–65 years (HR: 2.66; 95% CI 1.48–4.79); ≥ 65 years (HR: 3.77; 95% CI 2.09–6.78)]. Obese (BMI > 30 kg/m 2 ) survivors had a 4.06‐fold increase in the risk of type II DM compared to normal BMI (18–24.9 kg/m 2 ) cancer survivors. Cancer treatment did not increase the risk of type II DM compared to no treatment. Conclusions Adult B‐NHL cancer survivors were at an overall increased risk of developing type II DM compared to the general population, within the first year and overall, following a cancer diagnosis. This study provides evidence suggesting the importance of obesity prevention and improvement in care management oversight for B‐NHL survivorship and DM outcomes.
Journals
2026 EN
Salomon Amelie L. · Ammann Roland A. · Aftandilian Catherine
+14 more
ABSTRACT Purpose Fever in neutropenia (FN) is a potentially lethal complication of chemotherapy for cancer. Prompt administration of broad‐spectrum antibiotics is standard of care. Despite conflicting results on the association of time to antibiotics (TTA) with outcomes, TTA limits are used as FN quality measure both in adult and pediatric oncology. This individual patient data (IPD) meta‐analysis studied the association between TTA and outcomes in pediatric patients with FN. Patients and Methods IPD on TTA in pediatric patients with FN receiving chemotherapy for any malignancy was collected internationally. Three‐level mixed binomial logistic regression analyzed the association of TTA with safety relevant events (SRE; death, admission to intensive care unit [ICU], bacteremia), primarily in patients with severe disease at presentation and secondarily in all patients. Results Data on 4006 FN episodes in 2073 patients, diagnosed 2016–2023, were reported from 15 study sites in eight countries. Median TTA was 61 min overall and 53 min in the 345 (8.6%) episodes with severe disease at presentation. Among these with severe disease, an SRE was reported in 119 (34%) episodes. Longer TTA (> 60 vs. ≤ 60 min) was associated with less SRE (odds ratio, 0.41; 95% CI, 0.24–0.70). This primary finding was confirmed in secondary and additional exploratory analyses. Conclusion This large, international and adequately powered IPD meta‐analysis found no association between shorter TTA and improved clinical outcomes in pediatric patients with FN. This finding was consistent across analyses. These results challenge the continued use of TTA limits as a quality measure for pediatric oncology centers.
Journals
2026 EN
Morelle Axel · Dechenne Juhans · Caruano Joséphine
+5 more
ABSTRACT Fatty acid amide hydrolase (FAAH) inhibition holds therapeutic promise by enhancing endocannabinoid signaling. We previously identified β‐lactam compounds as reversible and selective h FAAH inhibitors with nanomolar potency. Here, we describe the synthesis of new β‐lactam derivatives to evaluate the effect of imide conformational constraints on activity and to eliminate potential metabolic soft spots. Bicyclic derivatives were designed to lock the imide in a syn configuration, but showed reduced potency compared with non‐cyclic analogs. Docking studies revealed that this weaker inhibition arises from an altered binding mode within the FAAH active site. In parallel, removal of ester and allyl groups did not affect inhibitory potency. Importantly, the optimized inhibitor enhanced N ‐acylethanolamine levels in J774 cells, supporting target engagement and suggesting improved metabolic stability. These results provide insights into the mode of action of β‐lactam FAAH inhibitors and guide the development of more potent, stable derivatives.
Journals
2026 EN
Guilleminot Pierre · Richard Carole · Roger Antoine
+5 more
ABSTRACT Background Left atrial appendage occlusion (LAAO) has become a valuable alternative to long‐term anticoagulation for stroke prevention in patients with non‐valvular atrial fibrillation (AF), especially in those at high bleeding risk. Hypoattenuated thickening (HAT) and device‐related thrombus (DRT) remain notable postprocedural concerns. Identifying reliable predictors is essential to optimize post‐LAAO management. Aims The aim of this study was to assess the incidence of HAT and DRT at 3 months following percutaneous LAAO and to identify clinical, anatomical, and procedural predictors—based on CT imaging evaluation—that may guide optimization of postprocedural antithrombotic strategies. Methods We conducted a retrospective single‐center study including adult patients who underwent percutaneous LAAO with Amplatzer Amulet or ACP devices at Dijon University Hospital between April 2016 and May 2024, with available pre‐ and 3‐month postprocedural CT scans. Baseline clinical, echocardiographic, biological, procedural, and anatomical data were collected. The primary objective was to determine the incidence and predictors of HAT and DRT at 3 months. Results Among 102 patients (mean age 76 ± 7 years, mean CHADS‐VASc 4.4 ± 1.4), HAT was observed in 25 (24%), and DRT in 3 (2.9%). Female sex and prior stroke/TIA were significantly associated with HAT occurrence. Importantly, patients discharged on dual antiplatelet therapy (DAPT) demonstrated a markedly lower incidence of HAT/DRT, suggesting a protective effect. In contrast, no anatomical parameter, including the Cressa classification, predicted thrombotic events. While Cressa morphology correlated with procedural complexity, it had no value for thrombotic risk stratification. Conclusions This study highlights the absence of anatomical predictors of HAT/DRT, emphasizing instead clinical determinants and the protective role of DAPT. These findings support tailoring antithrombotic therapy after LAAO according to individual clinical risk profiles, particularly in patients with prior stroke/TIA or women, who may benefit from reinforced preventive strategies. Larger multicenter studies are needed to refine postprocedural management algorithms and improve risk stratification beyond anatomical assessment.
Journals
2026 EN
Matarneh Ahmad Samir · Matarneh Bayan · Salameh Omar K.
+4 more
ABSTRACT Amyloid deposition is an increasingly recognized contributor to chronic kidney disease and end‐stage renal disease. It can result from various underlying conditions, including monoclonal gammopathies and chronic inflammatory states. Diagnosis is typically established by kidney biopsy demonstrating characteristic amyloid deposits. ALECT2 (leukocyte chemotactic factor 2) amyloidosis can present as nephrotic‐range proteinuria. ALECT2 amyloidosis is an uncommon and under‐recognized.
Journals
2026 EN
Bakari Rajabu Athumani · Chibwae Alfred · Mwinyi Amour Ally
+6 more
ABSTRACT Gastric inflammatory myofibroblastic tumor is a rare entity in children that may present with nonspecific gastrointestinal symptoms. Complete surgical excision remains both diagnostic and curative, with favorable postoperative outcomes and low recurrence risk when adequately resected.
Journals
2026 EN
Qi Meizhu · Won Julia · Rodriguez Catherine
+1 more
ABSTRACT The direct pathway from the lateral hypothalamus to the mouse olfactory bulb (OB) includes neurons that express the neuropeptide orexin‐A and others that do not. The OB‐projecting neurons that do not express orexin‐A are located in an area of the lateral hypothalamus known to contain neurons that express the neuropeptide melanin‐concentrating hormone (MCH). We used virally mediated anterograde tract tracing and immunohistochemistry for orexin‐A and MCH to demonstrate that the OB is broadly innervated by axon projections from both populations of neurons with expression in each OB layer across the anterior‐to‐posterior axis and which overlapped with synaptophysin. Both orexin‐A and MCH neurons are genetically heterogeneous, with subsets that co‐express an isoform of vesicular glutamate transporter (VGLUT). We used confocal imaging to test whether the projections from orexin‐A and MCH neurons to the OB reflect this glutamatergic heterogeneity. The majority of putative orexin‐A axon terminals overlapped with VGLUT2, with smaller proportions that co‐expressed VGLUT1 or that did not overlap with either VGLUT1 or VGLUT2. In contrast, a smaller proportion of MCH axon terminals overlapped with VGLUT2, with the majority being non‐glutamatergic. Therefore, the projections from the lateral hypothalamus to the OB are genetically heterogeneous and include neurons that can release two different neuropeptides. The projections from orexin‐A and MCH neuron populations are each genetically heterogeneous, with differing proportions of glutamatergic and non‐glutamatergic axon terminals.
Journals
2026 EN
Almansa Alexandra Santana · Landers Jessica R. · Abend Nicholas S.
+13 more
ABSTRACT Objective Most antiseizure medications (ASMs) are prescribed off label for neonates. Lacosamide's efficacy in infants and availability in intravenous formulation suggest potential utility for neonates. We evaluated the safety and efficacy of lacosamide for neonatal seizures. Methods This 10‐center, retrospective study of neonates with seizures and lacosamide treatment initiated by ≤ 48 weeks postmenstrual age collected clinical data from medical records and electroencephalogram recordings. Lacosamide efficacy was determined by changes in seizure burden with lacosamide treatment and seizure cessation by hospital discharge. Potential adverse events were reviewed. Results Among 62 eligible neonates, 33 had acute provoked seizures while 29 had neonatal‐onset epilepsy; there was no difference in seizure type or baseline seizure severity between groups. There were high rates of pretreatment status epilepticus (48%) and treatment‐resistant seizures, with 93% receiving ≥ 3 ASMs before lacosamide. Most received intravenous lacosamide, with a median loading dose of 5.0 mg/kg and median daily dose of 7.3 mg/kg. Seizure cessation occurred in 37% of neonates; 21% had no additional ASM administered after lacosamide. Seizure burden, measured in seizure minutes per hour, was lower at both 4 h and 7 days following lacosamide administration. In addition, there was a median reduction in seizure frequency of 30 seizures per day at 7 and 30 days posttreatment ( p < .05). Lacosamide was continued at discharge in most neonates (72%). Seventy adverse events were reported in 35 (56%) neonates. Four transient events with possible or unknown relationship to lacosamide were likely multifactorial in origin; none were cardiac arrhythmias. Summary Despite high rates of treatment‐resistant seizures in this neonatal cohort, 37% experienced seizure cessation and most remained on lacosamide at hospital discharge. Most adverse events were not attributed to lacosamide. These results favor use of lacosamide and provide a rationale for future prospective studies.
Journals
2026 EN
Gorbenko Andriy A. · Cuba Catherine M.K.E. · Goede Annika A.
+5 more
Cannabidiol (CBD) is approved as an adjunctive treatment of seizures associated with Dravet syndrome, Lennox–Gastaut Syndrome, and tuberous sclerosis. Its therapeutic and adverse effects are thought to arise, at least partly, from a pharmacokinetic interaction with clobazam, another anti‐seizure medication (ASM). The goal of this study was to evaluate the intrinsic anti‐epileptic and sedative properties of CBD. A randomized, double‐blind, placebo‐controlled, 3‐way crossover trial was conducted in 25 healthy males. On each visit, single doses of 30 mg CBD, 700 mg CBD, or placebo were administered orally. The effects of CBD on cortical excitability were measured using transcranial magnetic stimulation (TMS) combined with electromyography (EMG) and electroencephalography (EEG). Sedative properties were assessed using a validated CNS test battery. Pharmacokinetic sampling was performed. Data were analyzed using a mixed‐effects model. CBD did not have significant effects on single pulse and paired pulse TMS‐EMG parameters, compared to placebo. Some significant clusters were seen on paired pulse TMS‐EEG at 3 hours post‐dose for 30 mg CBD, and at 3 and 5 hours post‐dose for 700 mg CBD. CBD did not have significant effects on any tests assessing its sedative properties. These results suggest that CBD may lack intrinsic anti‐epileptic and sedative properties and that its effects could be primarily a product of interactions with other drugs, notably clobazam.